The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost

A salama; Nicole de Rosa; Randall Scheri; James Herndon; D Tyler; Jennifer Marcello; Scott Pruitt; Amy Abernethy

doi:10.3109/07357907.2012.726387

The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost

A salama, Nicole de Rosa, Randall Scheri, James Herndon, D Tyler, Jennifer Marcello, Scott Pruitt, Amy Abernethy

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Objectives: Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients. Methods: MM patients were identified from a prospectively maintained database, and a linear model predicting AYLL was developed. Results: Between 1970 and 1999, 4,774 patients diagnosed with MM died. The AYLL was 23.2 years. AYLL remained stable across three decades. Conclusions: AYLL for MM is greater than 20 years, and has not improved. This burden underscores the need for continued research and access to funding for this disease.

Original language	English
Pages (from-to)	637-641
Number of pages	5
Journal	Cancer Investigation
Volume	30
Issue number	9
DOIs	https://doi.org/10.3109/07357907.2012.726387
Publication status	Published - Nov 2012

Keywords

Life expectancy
Melanoma
Mortality
Potential years of life lost
Survival

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/07357907.2012.726387

Cite this

@article{dd9a5ad1f1aa4f408e8f7baf2259a6fe,

title = "The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost",

abstract = "Objectives: Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients. Methods: MM patients were identified from a prospectively maintained database, and a linear model predicting AYLL was developed. Results: Between 1970 and 1999, 4,774 patients diagnosed with MM died. The AYLL was 23.2 years. AYLL remained stable across three decades. Conclusions: AYLL for MM is greater than 20 years, and has not improved. This burden underscores the need for continued research and access to funding for this disease.",

keywords = "Life expectancy, Melanoma, Mortality, Potential years of life lost, Survival",

author = "A salama and {de Rosa}, Nicole and Randall Scheri and James Herndon and D Tyler and Jennifer Marcello and Scott Pruitt and Amy Abernethy",

year = "2012",

month = nov,

doi = "10.3109/07357907.2012.726387",

language = "English",

volume = "30",

pages = "637--641",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost

AU - salama, A

AU - de Rosa, Nicole

AU - Scheri, Randall

AU - Herndon, James

AU - Tyler, D

AU - Marcello, Jennifer

AU - Pruitt, Scott

AU - Abernethy, Amy

PY - 2012/11

Y1 - 2012/11

N2 - Objectives: Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients. Methods: MM patients were identified from a prospectively maintained database, and a linear model predicting AYLL was developed. Results: Between 1970 and 1999, 4,774 patients diagnosed with MM died. The AYLL was 23.2 years. AYLL remained stable across three decades. Conclusions: AYLL for MM is greater than 20 years, and has not improved. This burden underscores the need for continued research and access to funding for this disease.

AB - Objectives: Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients. Methods: MM patients were identified from a prospectively maintained database, and a linear model predicting AYLL was developed. Results: Between 1970 and 1999, 4,774 patients diagnosed with MM died. The AYLL was 23.2 years. AYLL remained stable across three decades. Conclusions: AYLL for MM is greater than 20 years, and has not improved. This burden underscores the need for continued research and access to funding for this disease.

KW - Life expectancy

KW - Melanoma

KW - Mortality

KW - Potential years of life lost

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84867721516&partnerID=8YFLogxK

U2 - 10.3109/07357907.2012.726387

DO - 10.3109/07357907.2012.726387

M3 - Article

SN - 0735-7907

VL - 30

SP - 637

EP - 641

JO - Cancer Investigation

JF - Cancer Investigation

IS - 9

ER -

The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this